Form 4: Stoke Therapeutics Director Boosts Stake via RSU Exercise

Stoke Therapeutics Director Edward M. Kaye exercised restricted stock units, increasing his direct beneficial ownership of common stock.

Summary

• Edward M. Kaye, MD, a Director of Stoke Therapeutics, Inc. (STOK), reported changes in beneficial ownership on March 15, 2026.
• Dr. Kaye acquired 35,500 shares of Common Stock upon the settlement of Restricted Stock Units (RSUs) at an exercise price of $0.
• Following this transaction, his direct beneficial ownership of Common Stock increased to 84,624 shares.
• An additional 26,250 shares of Common Stock were acquired from RSU settlement at an exercise price of $0 on the same date.
• This second transaction further increased his direct beneficial ownership of Common Stock to 110,874 shares.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.
• The 35,500 RSUs vested as to 1/4 of the total shares annually beginning March 15, 2024, with an expiration date of March 15, 2027.
• The 26,250 RSUs vested as to 1/4 of the total award annually beginning March 15, 2025, with an expiration date of March 15, 2028.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting a routine compensation action that increases a director's direct stake in the company, which can be seen as a positive alignment of interests.

Positives

• Increased direct beneficial ownership of common stock by a director, signaling continued alignment with shareholder interests.
• Transactions were executed under a Rule 10b5-1(c) plan, indicating pre-planned, non-discretionary trades.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it primarily reports past insider transactions.

Industry Context

StockSavvy.ai notes that the exercise of Restricted Stock Units (RSUs) is a standard component of executive and director compensation packages in the biotechnology industry, designed to align long-term incentives with company performance.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased direct ownership by a director may be viewed positively as it aligns the director's interests with those of shareholders.

Next Steps

• Continued vesting of remaining Restricted Stock Units, subject to Dr. Kaye's continued service to the Issuer.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to compensation. While an increase in director ownership is generally a positive signal, these are not open market purchases and do not provide new fundamental information about the company's operational performance or future prospects that would warrant a change in investment recommendation based solely on this filing. Investors should consider broader company fundamentals and market conditions.

Keywords

Stoke Therapeutics, STOK, Form 4, insider transaction, RSU exercise, beneficial ownership, director stock, Rule 10b5-1